Physician profile

David L Partee

Nurse Anesthetist, Certified Registered · Nashville, TN

NPI 1700872942

$782.16

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$328.23

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $563.46 2021-2024
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $61.26 2022
Takeda Pharmaceuticals U.S.A., INC. $55.11 2022
Nestle Healthcare Nutrition INC. $38.54 2022
Redhill Biopharma INC. $25.57 2022
Heron Therapeutics, INC. $20.87 2024 Aponvie
Regeneron Healthcare Solutions, INC. $17.35 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

David L Partee

$782.16

in general payments reported 2019-2025

Years
2021-2024
Top company
Abbvie INC.

https://glasscript.com/doctor/10501296/david-l-partee

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.